Fig. 1: Tumor-informed ctDNA workflow and swimmer plot for the entire cohort.

A Pretreatment FFPE tumor tissue from patients with HPV-independent HNSCC undergoing ICB therapy was obtained. DNA was extracted specimens with >20% of tumor component, and WES was performed to identify somatic mutations used to create personalized assays (RaDaR) for each patient. Plasma was obtained before and during ICB treatment, and each plasma sample was assessed for ctDNA detection. B Swimmer plot shows longitudinal monitoring of ctDNA, treatment, and response. CR complete response, PD progressive disease, PR partial response, SD stable disease. Patients 6, 8, 10 and 14 received a combination of immunotherapy plus chemotherapy. Patient 7 received Pembrolizumab plus ALX148 (anti-CD47).